Robert Harrington to Apolipoproteins B
This is a "connection" page, showing publications Robert Harrington has written about Apolipoproteins B.
Connection Strength
0.079
-
Apolipoprotein B, Residual Cardiovascular Risk After Acute Coronary Syndrome, and Effects of Alirocumab. Circulation. 2022 Aug 30; 146(9):657-672.
Score: 0.050
-
Effect of alirocumab, a monoclonal antibody to PCSK9, on long-term cardiovascular outcomes following acute coronary syndromes: rationale and design of the ODYSSEY outcomes trial. Am Heart J. 2014 Nov; 168(5):682-9.
Score: 0.029